| Date | Title | Description |
| 10.07.2026 | XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease | Financing round led by new investor Jeito Capital with participation from existing investors
Proceeds will support two double-blind Phase 2 clinical trials of lead candidate, XC001, which has demonstrated transformative potential for treatm... |
| 10.07.2026 | XyloCor Appoints John Tucker as President and Chief Executive Officer | XyloCor Therapeutics, Inc. (XyloCor or the Company), a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, today announced the appointment of John Tucker as President and Chief Exe... |
| 10.07.2026 | First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease | XC001 is a novel investigational therapy that previously demonstrated compelling efficacy and safety results, with disease-modifying potential, in patients with refractory angina in the EXACT-1 Phase 1/2 trial.
In the global EXACT-2 trial, ... |
| 11.07.2025 | First patient dosed in XyloCor Therapeutics’ Phase IIb trial using SmartCella’s Extroducer delivery platform | First patient dosed in XyloCor Therapeutics’ Phase IIb trial using SmartCella’s Extroducer delivery platform
Fri, Jul 11, 2025 09:30 CET Report this content
SmartCella Holding AB (“SmartCella”) today shares an update from XyloCor Therapeuti... |
| 09.01.2025 | The Rise of Unified Payments: Nomupay's Ambitious Expansion in Asia | In the bustling world of finance, where transactions flow like rivers, Nomupay is carving its path. This Dublin-based company has just secured $37 million in its third funding round, signaling a bold leap into the Asian market. With a missi... |
| 08.01.2025 | XyloCor Therapeutics Raises $67.5M in Series B Financing | XyloCor Therapeutics, a King of Prussia, PA-based clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, raised $67.5M in Series B financing.
The round was led by Jeito Capital with participatio... |
| 08.01.2025 | XyloCor Therapeutics: $67.5 Million (Series B) Raised For Advancing Clinical Development Of Gene Therapy In Cardiovascular Disease | XyloCor Therapeutics – a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease – announced the completion of a $67.5 million Series B financing. And the new investment will support a randomized,... |
| 08.01.2025 | A New Era in Investment Management with PAMM Accounts | Dubai, UAE, January 8th, 2025, FinanceWire
Achieving success in financial markets is often a challenging journey for many investors. Requiring both time management and market expertise, individual investors frequently struggle with inexperi... |
| 07.01.2025 | Jeito Capital's Bold Moves in Biopharma: A Strategic Investment Landscape | In the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm... |
| 07.01.2025 | French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics | Paris-based Jeito Capital, a PE fund focused on biopharma innovation, has furthered its position as a player in global healthcare investment with two major contributions to clinical-stage biotech companies Aviceda Therapeutics and XyloCor T... |
| 10.07.2024 | XyloCor and SmartCella enter into license agreement for use of the Extroducer to administer novel gene therapy XC001 to the heart | XyloCor and SmartCella enter into license agreement for use of the Extroducer to administer novel gene therapy XC001 to the heart
Wed, Jul 10, 2024 14:00 CET Report this content
The Extroducer® Infusion Catheter System ® enables local deliv... |
| 25.08.2023 |
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023 | Positive Phase 2 EXACT Trial results at 6-months underscore significant potential of investigational therapy in refractory angina
Six-month data have since been sustained out to 12-months supporting durability of XC001 safety and efficacy ... |
| 03.08.2023 |
Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions | Findings from the Phase 1 dose escalation portion of the EXACT trial of XC001 in refractory angina provided the dose selection and safety justification for the recently completed Phase 1/2 study
XC001 is a one-time gene therapy candidate d... |
| 18.07.2023 |
XyloCor Therapeutics Reports Sustained Results in 12- Month Extension of Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina | XC001 demonstrated durable improvements across multiple efficacy measures 12 months after treatment, underscoring its scientifically-sound approach to achieve biological effect and improve angina symptoms
Patients showed continued improvem... |
| 26.01.2023 | XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina | No serious adverse events related to drug product were reported
Patients demonstrated improvements in exercise capacity and reductions in episodes of chest pain
Cardiac imaging results provide mechanistic evidence supporting the therapeutic... |
| 26.01.2023 |
XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina | No serious adverse events related to drug product were reported
Patients demonstrated improvements in exercise capacity and reductions in episodes of chest pain
Cardiac imaging results provide mechanistic evidence supporting the therapeut... |
| 28.06.2022 | XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease | XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced it has achieved enrollment of target number of subjects in the Phase 2 portion of its ongoing Phase... |
| 28.06.2022 |
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease |
XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced it has achieved enrollment of target number of subjects in the Phase 2 portion of its ongoing Pha... |
| 18.05.2022 |
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT |
XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced presentation of initial clinical data from the Phase 1 portion of its ongoing Phase 1/2 clinical ... |
| 18.01.2022 |
XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth |
XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. Brian Davis as Chief ... |
| 27.07.2021 | XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina | Wayne, PA, July 27, 2021 – XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of the Phase 1 dose-escalation component of its Phase 1/2... |
| 27.07.2021 |
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina | XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of the Phase 1 dose-escalation component of its Phase 1/2 clinical trial (EXACT) of ... |
| 22.03.2021 | XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease | MALVERN, Pa.--(BUSINESS WIRE)--Mar 22, 2021--
XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, t... |
| 22.03.2021 | Lumira completes investment in XyloCor Therapeutics’ Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease | – Company closes additional $22.6 million in new financing – |
| 22.03.2021 | XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease | - |
| 22.03.2021 | XyloCor Therapeutics Closes $41.9M Series A Financing | XyloCor Therapeutics, a Malvern, Pa.-based private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, closed an additional $22.6m ... |
| 22.03.2021 |
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease |
XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, today announced the closing of an additional ... |
| 07.12.2018 | Term Sheet — Friday, December 7 | TIK-TOK
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Never heard of ByteDance? With a valuation of $75 billion (!), it’s the world’s most valuable startup. (I know, hard to be... |
| 07.12.2018 | Daily funding roundup - December 7th, 2018 | Akumina raised $7.5M; Trustology raised $8M; XyloCor Therapeutics raised $17M; EdCast raised $33.6M
OnSiteIQ: OnSiteIQ is a tech-enabled construction visual documentation and Risk Assessment service. OnSiteIQ has raised $2 million in seed f... |
| 06.12.2018 | XyloCor Therapeutics Raises $17 Million in Series A | - |
| 06.12.2018 | XyloCor Therapeutics Raises $17 Million in Series A | PHILADELPHIA--(BUSINESS WIRE)--XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, today announced the close of a $17 million Series ... |
| 06.12.2018 | XyloCor closes $17M Series A round to develop gene therapy for refractory angina | The company is planning to use the funding to advance development of its lead product candidate, XC001, a gene therapy for refractory angina. The therapy, which is currently in Phase I clinical development – with plans to initiate the trial... |
| - | XyloCor closes $17M Series A round to develop gene therapy for refractory angina | A company developing gene therapies for cardiovascular disease has secured its first major round of private financing.
Philadelphia-based XyloCor Therapeutics said Thursday that it closed a $17 million Series A funding round, co-led by Sofi... |
| - | XyloCor Therapeutics | “XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.” |
